MANNITOL 20% Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mannitol 20%, and what generic alternatives are available?
Mannitol 20% is a drug marketed by B Braun, Hospira, Miles, and Icu Medical Inc. and is included in six NDAs.
The generic ingredient in MANNITOL 20% is mannitol. There are eighteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the mannitol profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MANNITOL 20%?
- What are the global sales for MANNITOL 20%?
- What is Average Wholesale Price for MANNITOL 20%?
Summary for MANNITOL 20%
| US Patents: | 0 |
| Applicants: | 4 |
| NDAs: | 6 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 92 |
| Clinical Trials: | 225 |
| DailyMed Link: | MANNITOL 20% at DailyMed |
Recent Clinical Trials for MANNITOL 20%
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Hospital, Geneva | Phase 3 |
| Morten Hostrup, PhD | N/A |
| University Hospital Inselspital, Berne | Early Phase 1 |
Pharmacology for MANNITOL 20%
| Drug Class | Osmotic Diuretic |
| Mechanism of Action | Osmotic Activity |
| Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for MANNITOL 20%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B Braun | MANNITOL 20% | mannitol | INJECTABLE;INJECTION | 014738-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Miles | MANNITOL 20% | mannitol | INJECTABLE;INJECTION | 016472-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| B Braun | MANNITOL 20% | mannitol | INJECTABLE;INJECTION | 016080-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for MANNITOL 20%
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pharmaxis Europe Limited | Bronchitol | mannitol | EMEA/H/C/001252 Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care. |
Authorised | no | no | no | 2012-04-13 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
